The Global Product Strategy group is part of the Strategy and Portfolio Development (SPD) team. SPD is focused on fueling the growth of Takeda through our inline portfolio, lifecycle management, and rich pipeline. Our key goal is to commercialize our unprecedented pipeline that includes best-in-class and/or first-in-class therapies, many of which have complex or under-developed markets. Takeda is currently developing zasocitinib (TAK-279), an oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor, in several immune-mediated diseases. As zasocitinib progresses towards its initial launch in plaque psoriasis, Takeda is actively preparing for a subsequent indication launch in psoriatic arthritis (PsA).
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Mid Level